

Supplementary Table 2. Itemized analysis of BD patients who did not ANCA but could be reclassified as having OS-BD-GPA according to the 2022 ACR/EULAR criteria for GPA

Patient's number	Scores based on the 2022 ACR/EULAR criteria for GPA	1 (+3)	2 (+2)	3 (+1)	4 (+5)	5 (+2)	6 (+2)	7 (+1)	8 (+1)	9 (-1)	10 (-4)
1	5	0	0	1	0	1	1	0	0	0	0

1 = Nasal involvement (discharge, ulcers, crusting, congestion, septal defect/perforation); 2 = Cartilaginous involvement; 3 = Conductive or sensorineural hearing loss; 4 = PR3-ANCA (or C-ANCA) positivity; 5 = Pulmonary nodules, mass or cavitation; 6 = Granuloma, granulomatous inflammation, or giant cells on biopsy; 7 = Nasal/paranasal sinusitis or mastoiditis on imaging; 8 = Pauci-immune glomerulonephritis on biopsy; 9 = MPO-ANCA (or P-ANCA) positivity; 10 = Serum eosinophil count $\geq 1,000/\mu\text{L}$

BD, Behçet's disease; ANCA, antineutrophil cytoplasmic antibody; OS, overlap syndrome; GPA, granulomatosis with polyangiitis; ACR, the American College of Rheumatology; EULAR, the European Alliance of Associations for Rheumatology; PR3, proteinase 3; C, cytoplasmic; MPO, myeloperoxidase; P, perinuclear.